TABLE 1

Demographic and clinical characteristics of patients examined for PLD pharmacokinetics

Patient	Age	Histology	Presentation	Peritonectomy Procedures	PCI	Pharmacokinetic Sampling	Post-HIPEC Peritoneal Sampling
	years
1	64	Sarcoma	Primary	6	27	Perfusate and plasma	N.D.
2	46	Fallopian tube carcinoma	Recurrent	3	7	Perfusate and plasma	Peritoneum
3	59	EOC	Primary	2	9	Perfusate and plasma	Peritoneum (double sampling) carcinomatosis nodule
4	60	EOC	Primary	4	11	Perfusate and plasma	N.D.
5	74	EOC	Primary	4	11	Perfusate and plasma	Peritoneum (double sampling)
6	59	EOC	Primary	5	20	Perfusate and plasma	Peritoneum
7	59	EOC	Primary	5	10	Perfusate and plasma	Peritoneum
8	68	EOC	Primary	5	9	Perfusate and plasma	N.D.
9	57	EOC	Primary	6	30	Perfusate and plasma	N.D.
10	73	EOC	Primary	6	14	Perfusate and plasma	N.D.
11	54	EOC	Recurrent	2	25	Plasma	N.D.
12	71	EOC	Recurrent	2	2	Plasma	N.D.
13	76	EOC	Recurrent	3	4	Plasma	N.D.
14	68	EOC	Recurrent	3	3	Perfusate and plasma	N.D.
15	58	EOC	Recurrent	5	7	Perfusate and plasma	N.D.
16	59	EOC	Recurrent	6	16	Perfusate and plasma	N.D.
17	63	EOC	Recurrent	6	17	Perfusate and plasma	N.D.